Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension

<p><strong>Introduction</strong></p> Despite the increasing evidence supporting the efficacy of ambrisentan and bosentan in improving functional classes among pediatric patients with pulmonary arterial hypertension (PAH), there is a lack of information regarding their cost im...

Olles dieđut

Bibliográfalaš dieđut
Váldodahkkit: Buendia, JA, Patino, DG, Lindarte, EF
Materiálatiipa: Journal article
Giella:English
Almmustuhtton: Taylor and Francis 2023